Neuroectodermal Tumors clinical trials

The registry lists 29 studies for Neuroectodermal Tumors across more than 10 countries. 6 are recruiting or about to start. 2 of them are mainly about Neuroectodermal Tumors (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 35 narrower conditions too, such as Melanoma: 8,878 studies, 1,860 open.

Get an email when these change. Save the Neuroectodermal Tumors studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 14
Status unknown: 4
Recruiting: 3
Not yet recruiting: 3
Terminated: 2
Active, not recruiting: 1

Phase

Phase 1: 14
Phase 2: 13
Phase 3: 1

Where

United States: 17
Germany: 5
France: 5
China: 4
Spain: 4
Canada: 4

Who runs them

National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · DNAtrix, Inc. (2) · Taipei Medical University WanFang Hospital (1) · Jazz Pharmaceuticals (1) · Turning Point Therapeutics, Inc. (1) · Jubilant DraxImage Inc. (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1)

What is being tested here

Drugs under test in Neuroectodermal Tumors studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	All
G 207	1	1
Oncolytic HSV-1 G207	1	1
Repotrectinib	1	1
ONC206	0	1
Total Tumor mRNA-pulsed Tumor-specific Ex vivo-expanded Autologous Lymphocyte Transfer Cells	0	1
Pralsetinib	0	1
Tasadenoturev	0	1
Afatinib	0	1
Oncolytic Virus	0	1
Cixutumumab	0	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open

Coming up

1phase 3 study under way

1study finishes main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The study

Mar 2027Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms · Jazz Pharmaceuticals

Who these studies take

Of the 3 Neuroectodermal Tumors studies recruiting now, 1 (33%) set no upper age limit and 1 (33%) stop at 75 or younger. 2 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 3
Age	Women	Men
10	1 (33%)	1 (33%)
18	3 (100%)	3 (100%)
30	2 (67%)	2 (67%)
40	2 (67%)	2 (67%)
50	2 (67%)	2 (67%)
65	2 (67%)	2 (67%)
75	2 (67%)	2 (67%)
85	2 (67%)	2 (67%)

Across all 29 studies, recruiting or not: 45% stop at 75 or younger and 31% at 65; 48% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 29 of 29. search them.